BAYESIAN NETWORK META-ANALYSIS TO ASSESS THE COMPARATIVE EFFICACY AND SAFETY OF TREATMENTS FOR SEVERE OR UNCONTROLLED ASTHMA

Results
• This Bayesian network meta-analysis (NMA) aimed at assessing the relative efficacy and safety of monoclonal antibodies and a tyrosine-kinase inhibitor for severe or uncontrolled asthma based on studies identified via a systematic literature review.
This project was funded by Janssen A/S .
• This network meta-analysis of asthma treatments suggested that omalizumab had greater ACQ score reductions at 52 weeks than mepolizumab 75mg and 750mg but was comparable to mepolizumab 250mg. Active treatments were comparable regarding asthma exacerbations and discontinuations due to AE.
Change from baseline in ACQ score (Figure 2) • For ACQ score at 16 weeks, lebrikizumab 250 mg, omalizumab and placebo were comparable (P=45% to 64%). Only one study reported results for the comparison omalizumab versus placebo, which explains the broad credible interval.
• The analysis of ACQ score was not feasible at 26 weeks due to missing data.
• For ACQ score at 52 weeks, omalizumab ranked first, performed better than mepolizumab 75 mg and 750 mg (∆=0.25 and 0.20, P=91% and 86% respectively) and was comparable to mepolizumab 250 mg (P=75%).
• All mepolizumab doses were comparable and all active treatments performed better than placebo (P≥90%).
Asthma exacerbations (Figure 3)
• At 16 weeks, omalizumab ranked first based on the SUCRA, was comparable to masitinib (P=74%) and had lower exacerbation rates than placebo (OR=0.46, P=100%). Masitinib was comparable to placebo (P=76%).
• At 26 weeks, omalizumab had lower exacerbation rates than placebo (OR=0.53, P=100%).
• The analysis of exacerbations was not feasible at 52 weeks due to missing data.
Discontinuations due to AE
• At 16 weeks, omalizumab was comparable to placebo (P=79%).
• At 26 weeks, lebrikizumab 250 mg, omalizumab and placebo were comparable in terms of discontinuation rates (P=44% to 52%).
• At 52 weeks, mepolizumab 75 mg ranked first based on the SUCRA, was associated with less discontinuations due to AE than mepolizumab 750 mg (OR=0.47, P=91%) and was comparable to omalizumab, mepolizumab 250 mg and placebo (P=69% to 82%).
• Omalizumab was comparable to mepolizumab 250 mg, 750 mg and placebo (P=30% to 65%). Mepolizumab 250 mg was comparable to mepolizumab 750 mg and placebo (P=65% and 33% respectively).
Figure 1a. Network of evidence at 16 weeks
Methods
• Bayesian NMAs were conducted based on a systematic literature review. Methods were in line with NICE guidelines [6, 7] .
• Outcomes of interest included asthma control questionnaire (ACQ) score, asthma exacerbations and discontinuations due to adverse events (AE).
• Networks of evidence were based on treatment-and dose-specific nodes except for masitinib for which results were published only for pooled doses.
• Separate analyses were conducted at 16 weeks (± 4 weeks), 26 weeks (± 4 weeks) and 52 weeks (± 4 weeks).
• Relative efficacy was evaluated based on absolute differences (∆) or oddsratios (OR), Bayesian pairwise probabilities (P, i.e. probability to perform better) and ranking of treatments based on the surface under the cumulative ranking (SUCRA) [8] . The thresholds P≤15% and P≥85% were chosen to indicate a smaller and larger effect, respectively [9] .
• To assess heterogeneity, the I 2 statistic was calculated for each pairwise comparison. Heterogeneity was suspected if I 2 was higher than 50% . [10] • Vague prior distributions were used to produce results driven by the data.
The selection of using a fixed or random effects model was based on the Deviance Information Criterion (DIC), which measures the relative goodness of fit between models [11] .
• The systematic literature review led to the inclusion of 8 trials reporting results at 16 weeks (±4 weeks), 6 trials at 26 weeks (±4 weeks) and 3 trials at 52 weeks (±4 weeks). Treatments assessed were omalizumab, lebrikizumab, mepolizumab and masitinib.
• The limited reported data in the study publications [12, 13] led to restricted networks at 16 weeks (7 trials) and 26 weeks (5 studies) (figures 1a and 1b). The network at 52 weeks is reported in figure 1c.
• The DIC associated with the fixed effect model was lower than the DIC associated with the random effects model for all the outcomes and times of assessment, except for the discontinuations due to AE at 26 weeks. Therefore, the results based on the fixed effect model were chosen for all analyses, except for the discontinuations due to AE at 26 weeks for which the random effects model was selected. 
Discussion
• Few trials were included in each analysis resulting in broad credible intervals. Two trials assessed mepolizumab but the study by Ayars 2013 [13] did not report the same outcomes than other included studies. A single trial was identified assessing lebrikizumab [14] and only one trial assessed masitinib, which was a small trial with less than 50 patients in total [15] .
• Two trials [16, 17] were identified as potential sources of heterogeneity in the analyses of exacerbations at 16 weeks and discontinuations due to AE at 26 weeks respectively and were excluded as part of sensitivity analyses. Based on these results, omalizumab had a higher risk of discontinuations due to AE compared to placebo (OR=4.48, P=6%). 
